ArticleBMC complementary and alternative medicine2018
Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy.
Article in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Interventions for managing clinically relevant sleep disturbances or insomnia in cancer patients and survivors: an up-to-date systematic review and meta-analysis of self-reported sleep disturbance.Frontiers in psychology · 2026Pooled it
- Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL).Palliative medicine · 2026Trial
- Insights on supplement use during cancer care from online Reddit conversations.BMC complementary medicine and therapies · 2026Article
- Perspectives on the formalisation of complementary and alternative medicine among current users with prostate cancer: a study at Korle-Bu Teaching Hospital, Ghana.BMC complementary medicine and therapies · 2026Article
- Impact of risk and lifestyle factors on therapy goals in the treatment of breast cancer and gynecological cancer patients with integrative medicine.Archives of gynecology and obstetrics · 2025Article
- Therapeutic Efficacy ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Prevalence and associated factors of herbal medicine use among breast cancer patients: a cross-sectional study in Morocco.Ecancermedicalscience · 2024Article
- Biologically Based Complementary and Alternative Medicine Use in Breast Cancer Patients and Possible Drug-Drug Interactions.Breast care (Basel, Switzerland) · 2023Article
- Utilization of complementary and alternative medicine (CAM) by women with breast cancer or gynecological cancer.PloS one · 2023Article
- LC-PDA-MS and GC-MS Analysis ofInternational journal of molecular sciences · 2022Article
- Phytotherapy in Integrative Oncology-An Update of Promising Treatment Options.Molecules (Basel, Switzerland) · 2022Review
- A survey of multidisciplinary healthcare providers utilizing the KNOWintegrativeoncology.org educational platform.BMC complementary medicine and therapies · 2022Article
- The Role of Beetroot Extract in Overcoming Chemoresistance of Neoadjuvant Adriamycin Cyclophosphamide Regimen by Targeting Immune Response in Tumor Microenvironment: A Preclinical Study in Mammary Adenocarcinoma Rats.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Study of the Mechanism of Antiemetic Effect ofDrug design, development and therapy · 2022Article
- Additional treatment with mistletoe extracts for patients with breast cancer compared to conventional cancer therapy alone - efficacy and safety, costs and cost-effectiveness, patients and social aspects, and ethical assessment.German medical science : GMS e-journal · 2022Review
- Complementary medicine in Germany: a multi-centre cross-sectional survey on the usage by and the needs of patients hospitalized in university medical centers.BMC complementary medicine and therapies · 2021Article
- Dietary supplement use in ambulatory cancer patients: a survey on prevalence, motivation and attitudes.Journal of cancer research and clinical oncology · 2021Article
- Patterns and Trends of Herbal Medicine Use among Patients with Gynecologic Cancer.Geburtshilfe und Frauenheilkunde · 2021Article
- Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7.International journal of molecular sciences · 2020Article
- Comparison of gamma irradiation and heating treatment on cytotoxicity, insulinotropic activity, and molecular structure change of mistletoe viscothionin.Food science and biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiologically-based complementary medicines (BB-CAM) including herbs and nutritional supplements are frequently taken by breast- and gynecological cancer patients undergoing systemic therapy. The aim of this study was to analyze the use of these natural CAM methods under systemic therapy.
methodsFrom September 2014 to December 2014 and February 2017 to May 2017 all patients (n= 717) undergoing systemic therapy at the day care unit, Department of Gynecology and Obstetrics, Technical University Munich, Germany, with breast- and/or gynecological cancer were included in this survey. The self-administered 8-item questionnaire was developed to obtain information on complementary medication intake during systemic therapy.
resultsAmong 448 respondents 74.1% reported to use complementary medication simultaneous to their systemic therapy. The most frequently applied methods during therapy were vitamins and minerals supplements (72.3%), medicinal teas (46.7%), phytotherapy (30.1%), and mistletoe (25.3%). The analysis showed that various patients-, disease- and therapy characteristics like receiving chemotherapy (p= 0.002), and younger age (younger than 60 years; p=0.017) are significantly associated with BB-CAM use.
conclusionsOur data suggest that female cancer patients undergoing systemic therapy frequently use BB-CAM medicine. Therefore, it is indispensable to implement counseling and evidence-based complementary treatments into clinical routine of cancer centers. A counseling service for integrative medicine concepts and an outpatient program (ZIGG) was therefore implemented in our cancer center in 2013. Further research on the CAM intake of cancer patients is needed in order to verify drug interactions and implement specific guidelines for integrative medication concepts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.